The FDA alignment on the APOLLO trial design significantly de-risks bitopertin. Focus on Q4 2026 topline data from APOLLO and upcoming initial data from DISC-3405 (RESTORE-PV) in Q3 2026 as key catalysts. Monitor cash burn rate and any PDUFA timeline updates.
IRON drugs
IRON drug pipeline →Price Chart
Executive Summary
Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), slightly narrower than the $1.58 consensus. The key news is the completion of a Type A meeting with the FDA, aligning that the Phase 3 APOLLO study of bitopertin in EPP, if successful, can serve as the basis for a CRL response. The company also completed enrollment for the RESTORE-PV Phase 2 study of DISC-3405, with initial data now expected in Q3 2026, ahead of schedule. Cash position remains strong at $718M, providing runway into 2029.
Key Financial Metrics
Key Facts
- Completed Type A meeting with FDA: successful Phase 3 APOLLO can support CRL response for bitopertin in EPP; topline data expected Q4 2026
- Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera; initial data now expected Q3 2026
- Cash, cash equivalents, and marketable securities of $717.7M as of June 30, 2026, providing runway into 2029
- Net loss for Q2 2026 was $59.5M, net loss per share $(1.54) vs consensus $(1.58), a 2.5% beat
- Launched Expanded Access Program (EAP) for bitopertin in EPP patients
- Presented positive Phase 2 data for selcodebart (DISC-0974) in myelofibrosis anemia at ASCO and EHA
Financial Impact
Pre-revenue clinical-stage biotech; net cash burn of ~$59.5M in Q2; cash runway into 2029 covers all planned trials. The FDA alignment de-risks the bitopertin program, which could address a significant unmet need in EPP if approved.
Risk Factors
- Phase 3 APOLLO trial failure or underwhelming results
- Regulatory setbacks or delays in CRL response
- Clinical trial enrollment or data delays for DISC-3405 and selcodebart
- Cash burn rate may accelerate with multiple concurrent trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-325031 |
| Document: iron-20260730.htm | 0001193125-26-325031 |
| Document: 0001193125-26-325031-index-headers.html | 0001193125-26-325031 |
| Document: 0001193125-26-325031-index.html | 0001193125-26-325031 |
| Document: 0001193125-26-325031.txt | 0001193125-26-325031 |
| 8-K Data (Synthetic) | 0001193125-26-325031 |
Track record
43 reports on IRON
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers